Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28202627 | 0.87 | CHRNB2 (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL27379876 | 0.84 | HRH2 (0.32) | — | |
| SCHEMBL10961104 | 0.80 | ADRB1 (0.31) | HTR2CHTR2B | |
| SCHEMBL5919636 | 0.77 | — | — | |
| SCHEMBL28276943 | 0.76 | — | — | |
| SCHEMBL27464507 | 0.73 | HTR2C (0.30) | HTR2CHTR2B | |
| Water SCHEMBL27462314 | 0.71 | — | — | |
| SCHEMBL27599460 | 0.70 | — | — | |
| SCHEMBL6014549 | 0.70 | — | — | |
| SCHEMBL3026612 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0020303-B1 | GUANIDINES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS AND THEIR APPLICATION | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | claimed |
| CN-101868469-B | Phosphonic acid derivatives and their use as P2Y12Receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2014-04-02 | — | — | CN | disclosed |
| CN-103649055-A | Method for manufacturing pyrazole derivative | MITSUBISHI TANABE PHARMA CORP | 2014-03-19 | — | — | CN | disclosed |
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| CN-101663293-B | Quinoline-carboxamide derivatives as p2y12 antagonists | SANOFI AVENTIS SPA | 2013-07-31 | — | — | CN | disclosed |
| CN-1918137-B | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2012-08-01 | — | — | CN | disclosed |
| CN-101528715-B | 2-phenyl-6-aminocarbonyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| CN-1902196-B | Thiazole derivatives | KYOWA HAKKO KOGYO KK | 2010-12-29 | — | — | CN | disclosed |
| CN-101868469-A | Phosphonic acid derivatives and their use as P2Y12ReceptorsAntagonists | ACTELION PHARMACEUTICALS LTD | 2010-10-20 | — | — | CN | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
| CN-1805965-A | Modulators of chemokine receptor activity | MERCK & CO INC (US) | 2006-07-19 | — | — | CN | disclosed |
| CN-1531538-A | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidie derivatives | ��˹��ŵ�� | 2004-09-22 | — | — | CN | disclosed |
| CN-1474813-A | Substituted 2-phenylaminoimidazolinylphenyl ketone derivatives as IP antagonists | - | 2004-02-11 | — | — | CN | disclosed |
| CN-1127493-C | 1-(N-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of phenyl ring | RECORDATI CHEM PHARM (CH) | 2003-11-12 | — | — | CN | disclosed |
| CN-1265654-A | 1-(N-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of phenyl ring | RECORDATI CHEM PHARM (CH) | 2000-09-06 | — | — | CN | disclosed |
| CN-1051299-C | Tetrahydrophthamide derivative medium for preparation of same, preparation of same and herbcide which uses same as effective composition | SAGAMI CHEM RES (JP) | 2000-04-12 | — | — | CN | disclosed |
| CN-1084847-A | Tetrahydrochysene butyl benzene orthobenzol diacid amide derivative and its preparation intermediate and manufacture method thereof and with its weedicide as effective constituent | SAGAMI CHEM RES (JP) | 1994-04-06 | — | — | CN | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0076996-B1 | CARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
| EP-0035363-B1 | INDANE DERIVATIVES, METHODS OF THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | KEFALAS A/S (DK) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | HTR2C 679/4885HTR2B 303/4885CHRNB2 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.